JP3681401B2 - 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用 - Google Patents
感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用 Download PDFInfo
- Publication number
- JP3681401B2 JP3681401B2 JP50569198A JP50569198A JP3681401B2 JP 3681401 B2 JP3681401 B2 JP 3681401B2 JP 50569198 A JP50569198 A JP 50569198A JP 50569198 A JP50569198 A JP 50569198A JP 3681401 B2 JP3681401 B2 JP 3681401B2
- Authority
- JP
- Japan
- Prior art keywords
- recombinant virus
- infectious recombinant
- virus according
- aqueous
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 123
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 82
- 230000002458 infectious effect Effects 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000000725 suspension Substances 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 44
- 229930006000 Sucrose Natural products 0.000 claims abstract description 44
- 239000005720 sucrose Substances 0.000 claims abstract description 44
- 239000007864 aqueous solution Substances 0.000 claims abstract description 37
- 239000000243 solution Substances 0.000 claims abstract description 26
- 230000003612 virological effect Effects 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000007900 aqueous suspension Substances 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 19
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000000739 chaotic effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 4
- 239000007998 bicine buffer Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007997 Tricine buffer Substances 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000010316 Myotonia congenita Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000013598 vector Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000012537 formulation buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- -1 1 mM of MgCl 2 Chemical compound 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001440741 CHER virus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608851A FR2751343B1 (fr) | 1996-07-16 | 1996-07-16 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| FR96/08851 | 1996-07-16 | ||
| PCT/FR1997/001308 WO1998002522A1 (fr) | 1996-07-16 | 1997-07-15 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000500026A JP2000500026A (ja) | 2000-01-11 |
| JP2000500026A5 JP2000500026A5 (cg-RX-API-DMAC10.html) | 2004-10-21 |
| JP3681401B2 true JP3681401B2 (ja) | 2005-08-10 |
Family
ID=9494078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50569198A Expired - Lifetime JP3681401B2 (ja) | 1996-07-16 | 1997-07-15 | 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6451256B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP0853660B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP3681401B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE231549T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU711409B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2232604C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69718612T2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0853660T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2187798T3 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2751343B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998002522A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| AU773834B2 (en) * | 1998-12-03 | 2004-06-10 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| KR20020013521A (ko) * | 1999-04-09 | 2002-02-20 | 추후제출 | 감염성 재조합 아데노바이러스 보존용 조성물 |
| FR2791999B1 (fr) * | 1999-04-09 | 2001-09-07 | Aventis Pharma Sa | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| JP5118798B2 (ja) * | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| AU2001256675A1 (en) * | 2000-05-10 | 2001-11-20 | Mitsubishi Pharma Corporation | Method of preparing virus vector |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| CA2469721A1 (en) * | 2002-01-18 | 2003-07-31 | Schering Aktiengesellschaft | Stabilized formulations of adenovirus |
| KR100507794B1 (ko) * | 2003-02-11 | 2005-08-17 | 한미약품 주식회사 | 고농도 레트로 바이러스 현탁액 제조 방법 |
| WO2005052116A2 (en) * | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
| WO2005080556A2 (en) * | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| AU2006233800B2 (en) * | 2005-04-11 | 2011-07-07 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| NZ593235A (en) | 2008-11-03 | 2013-02-22 | Crucell Holland Bv | Method for the production of recombinant adenovirus serotype 35 |
| PL2536829T3 (pl) | 2010-02-15 | 2016-09-30 | Sposób wytwarzania wektorów adenowirusowych Ad26 | |
| WO2012038367A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| CA2809463C (en) | 2010-09-27 | 2021-05-25 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| CA2819236A1 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
| MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| EA029492B1 (ru) | 2012-07-10 | 2018-04-30 | Трансген Са | Вакцина на основе микобактериальных антигенов |
| EP3488864A1 (en) | 2013-04-25 | 2019-05-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| US9721484B2 (en) | 2014-06-23 | 2017-08-01 | Humanetics Innovative Solutions, Inc. | Shoulder kit assembly for crash test dummy |
| CN120555373A (zh) | 2014-07-16 | 2025-08-29 | 特兰斯吉恩股份有限公司 | 用于表达免疫检查点调节因子的溶瘤病毒 |
| US10008130B2 (en) | 2014-09-17 | 2018-06-26 | Humanetics Innovative Solutions, Inc. | Omni-directional shoulder assembly for crash test dummy |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
| EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| CN116059336A (zh) | 2015-07-07 | 2023-05-05 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| MD3439672T2 (ro) | 2016-04-05 | 2021-04-30 | Janssen Vaccines & Prevention Bv | Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV |
| PE20190433A1 (es) | 2016-04-05 | 2019-03-21 | Janssen Vaccines And Prevention B V | Vacuna contra vrs |
| ES2829272T3 (es) | 2016-05-12 | 2021-05-31 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado |
| DK3464331T3 (da) | 2016-05-30 | 2021-01-18 | Janssen Vaccines & Prevention Bv | Stabiliserede præfusions-rsv f-proteiner |
| WO2017220499A1 (en) | 2016-06-20 | 2017-12-28 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｐｖワクチン |
| WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
| AU2018217935B2 (en) | 2017-02-09 | 2020-04-30 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| EA202090738A1 (ru) | 2017-09-15 | 2020-06-10 | Янссен Вэксинс Энд Превеншн Б.В. | Способ безопасного индуцирования иммунитета против rsv |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| PH12021550974A1 (en) | 2018-11-13 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Stablized pre-fusion rsv f proteins |
| CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
| IL296520A (en) | 2020-03-19 | 2022-11-01 | Trizell Ltd | Temperature-responsive virus storage system |
| EP4178605A1 (en) | 2020-07-13 | 2023-05-17 | Transgene | Treatment of immune depression |
| EP4303233A4 (en) | 2021-02-01 | 2025-05-07 | St Phi Therapeutics Co., Ltd. | Targeted protein degradation system and use thereof |
| CA3211034A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| EP4547705A1 (en) | 2022-07-01 | 2025-05-07 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5658779A (en) * | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| EP0728195A1 (en) * | 1993-10-12 | 1996-08-28 | Chiron Corporation | Methods for preserving recombinant viruses |
| FR2711523B1 (fr) * | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
-
1996
- 1996-07-16 FR FR9608851A patent/FR2751343B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-15 JP JP50569198A patent/JP3681401B2/ja not_active Expired - Lifetime
- 1997-07-15 EP EP97933740A patent/EP0853660B1/fr not_active Expired - Lifetime
- 1997-07-15 AU AU36986/97A patent/AU711409B2/en not_active Expired
- 1997-07-15 AT AT97933740T patent/ATE231549T1/de active
- 1997-07-15 US US09/043,187 patent/US6451256B1/en not_active Expired - Lifetime
- 1997-07-15 WO PCT/FR1997/001308 patent/WO1998002522A1/fr not_active Ceased
- 1997-07-15 DK DK97933740T patent/DK0853660T3/da active
- 1997-07-15 ES ES97933740T patent/ES2187798T3/es not_active Expired - Lifetime
- 1997-07-15 CA CA002232604A patent/CA2232604C/fr not_active Expired - Lifetime
- 1997-07-15 DE DE69718612T patent/DE69718612T2/de not_active Expired - Lifetime
-
2002
- 2002-08-15 US US10/218,564 patent/US20030082206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000500026A (ja) | 2000-01-11 |
| US6451256B1 (en) | 2002-09-17 |
| DE69718612D1 (de) | 2003-02-27 |
| DE69718612T2 (de) | 2003-11-06 |
| ES2187798T3 (es) | 2003-06-16 |
| EP0853660B1 (fr) | 2003-01-22 |
| AU3698697A (en) | 1998-02-09 |
| FR2751343B1 (fr) | 1998-12-18 |
| WO1998002522A1 (fr) | 1998-01-22 |
| AU711409B2 (en) | 1999-10-14 |
| CA2232604C (fr) | 2005-06-28 |
| ATE231549T1 (de) | 2003-02-15 |
| FR2751343A1 (fr) | 1998-01-23 |
| US20030082206A1 (en) | 2003-05-01 |
| DK0853660T3 (da) | 2003-05-05 |
| EP0853660A1 (fr) | 1998-07-22 |
| CA2232604A1 (fr) | 1998-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3681401B2 (ja) | 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用 | |
| US6805858B1 (en) | Methods for the administration of adenovirus p53 | |
| ES2272053T3 (es) | Composiciones que comprenden virus y metodos para concentrar preparaciones de virus. | |
| JP3847334B2 (ja) | ＤＮＡ損傷剤およびр５３を含有する組成物 | |
| HU221340B1 (en) | Adenoviral vectors of animal origin and use thereof in gene therapy | |
| US9115374B2 (en) | SYN3 compositions and methods | |
| US20090215164A1 (en) | Recombinant gene of adenovirus vector and p53 gene for treating proliferative diseases | |
| AU2023393582A1 (en) | Tet-r expression cassettes and cell lines | |
| HK40083861A (en) | Pharmaceutical composition of recombinant adeno-associated virus vector and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050419 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050518 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100527 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110527 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110527 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120527 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130527 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |